Form 4: Gilde Healthcare Divests LAVA Therapeutics Shares

Gilde Healthcare, a 10% owner of LAVA Therapeutics NV, reported significant sales of common shares totaling over 2.8 million shares in October 2025.

Summary

• Cooperatieve Gilde Healthcare IV U.A., a 10% owner of LAVA Therapeutics NV (LVTX), reported multiple sales of common shares.
• On October 16, 2025, 690,239 common shares were sold at a weighted average price of $1.49 per share.
• On October 17, 2025, 1,181,131 common shares were sold at a weighted average price of $1.47 per share.
• On October 20, 2015, 1,000,000 common shares were sold at a weighted average price of $1.46 per share. (Note: This date appears to be a typo and likely intended to be 2025, given the other transaction dates and the filing date of October 20, 2025).
• Following these transactions, Cooperatieve Gilde Healthcare IV U.A. beneficially owns 1,947,781 common shares.
• The reported sales were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 3

Explanation: The sale of a substantial number of shares by a 10% owner, even if pursuant to a 10b5-1 plan, generally indicates a negative sentiment or a strategic divestment, which can put downward pressure on the stock price.

Negatives

• A significant 10% owner, Cooperatieve Gilde Healthcare IV U.A., has reduced its stake in LAVA Therapeutics NV by selling a total of 2,871,370 common shares across three reported transactions.
• The sales occurred at weighted average prices ranging from $1.46 to $1.49 per share, indicating a divestment at current market levels.

Industry Context

Insider selling by a significant institutional investor like Gilde Healthcare can sometimes be interpreted by the market as a signal regarding the company's near-term prospects or valuation, particularly in the biotechnology sector where capital raises and clinical milestones heavily influence stock performance. Such divestments, even if pre-planned, can lead to increased scrutiny from other investors.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential impact on future capital raising efforts if investors perceive a lack of long-term commitment from major shareholders.

Key Dates

Recommendation

The substantial divestment by a 10% owner, Gilde Healthcare, signals a potential lack of conviction in LAVA Therapeutics NV's near-term prospects or valuation. While executed under a 10b5-1 plan, the sheer volume of shares sold (over 2.8 million) at current price levels suggests a strategic reduction in exposure. This insider selling could exert downward pressure on the stock and warrants a 'sell' recommendation for investors looking to mitigate potential losses or reallocate capital to opportunities with stronger insider alignment.

Keywords

LAVA Therapeutics NV, LVTX, Gilde Healthcare, Insider Selling, Form 4, Share Sale, Beneficial Ownership, Equity Transaction, 10b5-1 Plan